GP
ALXN

GLG Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

GLG Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.15M Buy
9,602
+7,369
+330% +$897K 0.05% 276
2017
Q3 		$313K Sell
2,233
-10,001
-82% -$1.36M 0.02% 290
2017
Q2 		$1.49M Buy
12,234
+7,567
+162% +$881K 0.08% 222
2017
Q1 		$566K Buy
+4,667
New +$602K 0.03% 326
2016
Q4 		– Sell
-64,341
Closed -$7.88M – 484
2016
Q3 		$7.88M Sell
64,341
-106,420
-62% -$13.7M 0.24% 116
2016
Q2 		$19.9M Sell
170,761
-89,562
-34% -$12.7M 0.6% 40
2016
Q1 		$36.2M Buy
260,323
+25,313
+11% +$3.72M 1.03% 14
2015
Q4 		$44.8M Buy
235,010
+4,834
+2% +$844K 1.43% 10
2015
Q3 		$36M Buy
230,176
+192,176
+506% +$35.1M 0.95% 19
2015
Q2 		$6.87M Buy
+38,000
New +$6.56M 0.18% 145

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GLG Partners's ALXN Position: Q4 2017 in Review

GLG Partners increased its Alexion Pharmaceuticals (ALXN) stake by 330% in Q4 2017, buying an estimated $897K and bringing the position to 9,602 shares worth $1.15M. The position accounts for 0.05% of the portfolio, ranked #276.

GLG Partners first reported a position in ALXN in Q2 2015 and has held it in 10 quarters since. The position peaked at $44.8M in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • GLG Partners held 9,602 shares of Alexion Pharmaceuticals worth $1.15M as of Q4 2017.
  • GLG Partners bought 7,369 Alexion Pharmaceuticals shares in Q4 2017, an estimated $897K.
  • Alexion Pharmaceuticals made up 0.05% of GLG Partners's portfolio in Q4 2017, its #276 holding.
  • GLG Partners first reported a position in Alexion Pharmaceuticals in Q2 2015 and has held it in 10 quarters since.
  • GLG Partners's Alexion Pharmaceuticals position peaked at $44.8M in Q4 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.